Zymeworks Share Price Today
(NASDAQ: ZYME)

Name: Zymeworks Share Price Today (NASDAQ: ZYME) - Zymeworks Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Zymeworks share price is $13.18 & ₹1,146.25 as on 6 Mar 2025, 2.30 'hrs' IST

$13.18

▲

0.43

(3.37%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Zymeworks share price in Dollar and Rupees. Guide to invest in Zymeworks stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Zymeworks, along with analyst recommendations, forecasts, and comprehensive financials.

Zymeworks share price movements

Today's Low: $12.70
Today's High: $13.18
$13.18
3.66%
Downside
Day's Volatility :3.66%
Upside
0.0%
52 Weeks Low: $7.97
52 Weeks High: $17.70
$13.18
39.53%
Downside
52 Weeks Volatility :54.97%
Upside
25.54%

Zymeworks (ZYME) Returns

Period	Zymeworks Inc	Russel 2000	Index (Russel 2000)
3 Months	-10.21%	0.0%	0.0%
6 Months	8.42%	0.0%	0.0%
1 Year	4.25%	0.0%	0.0%
3 Years	104.0%	-11.6%	-11.6%

Zymeworks (ZYME) Key Statistics

in dollars & INR

Previous Close	$12.75
Open	$12.72
Today's High	$13.18
Today's Low	$12.6979
Market Capitalization	$877.5M
Today's Volume	$214.9K
52 Week High	$17.7
52 Week Low	$7.97
Revenue TTM	$62.2M
EBITDA	$-114.7M
Earnings Per Share (EPS)	$-1.49
Profit Margin	-182.75%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-28.73%

How to invest in Zymeworks Stock (ZYME) from India?

It is very easy for Indian residents to invest directly in Zymeworks from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Zymeworks stock in both Indian Rupees (INR) and US Dollars (USD). Search for Zymeworks or ZYME on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Zymeworks or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Zymeworks shares which would translate to 0.066 fractional shares of Zymeworks as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Zymeworks, in just a few clicks!

Returns in Zymeworks (ZYME) for Indian investors in Rupees

The Zymeworks stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Zymeworks investment value today

Current value as on today

₹1,12,731

Returns

₹12,731

(+12.73%)

Returns from Zymeworks Stock

₹7,768 (+7.77%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Zymeworks (ZYME)

-45%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Zymeworks Stock from India on INDmoney has decreased by -45% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Zymeworks

EcoR1 Capital, LLC
21.82%
Redmile Group, LLC
7.03%
Bvf Inc
6.26%
Morgan Stanley - Brokerage Accounts
6.10%
BlackRock Inc
6.08%
Rubric Capital Management LP
5.69%

Analyst Recommendation on Zymeworks

Buy

71%Buy

28%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Zymeworks(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Zymeworks Stock (ZYME)

What analysts predicted

Upside of 55.06%

Target:

$20.44

Current:

$13.18

Insights on Zymeworks Stock (Ticker Symbol: ZYME)

Price Movement
In the last 3 years, ZYME stock has moved up by 106.3%
Decreasing Revenue
Revenue is down for the last 2 quarters, 19.24M → 16.0M (in $), with an average decrease of 16.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -37.68M → -29.85M (in $), with an average increase of 26.3% per quarter
ZYME vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 55.9%
Price to Sales
ForZYME every $1 of sales, investors are willing to pay $15.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

ZYME Zymeworks Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$53.0M	↑ 2.43%
Net Income	$-36.6M	↑ 251.3%
Net Profit Margin	-68.95%	↓ 48.85%

	FY19	Y/Y Change
Revenue	$29.5M	↓ 44.28%
Net Income	$-145.4M	↑ 297.85%
Net Profit Margin	-492.27%	↓ 423.32%

	FY20	Y/Y Change
Revenue	$39.0M	↑ 31.84%
Net Income	$-180.6M	↑ 24.14%
Net Profit Margin	-463.54%	↑ 28.73%

	FY21	Y/Y Change
Revenue	$26.7M	↓ 31.5%
Net Income	$-211.8M	↑ 17.33%
Net Profit Margin	-794.01%	↓ 330.47%

	FY22	Y/Y Change
Revenue	$412.5M	↑ 1446.03%
Net Income	$124.3M	↓ 158.69%
Net Profit Margin	30.14%	↑ 824.15%

	FY23	Y/Y Change
Revenue	$76.0M	↓ 81.57%
Net Income	$-118.7M	↓ 195.44%
Net Profit Margin	-156.13%	↓ 186.27%

	Q2 FY23	Q/Q Change
Revenue	$7.0M	↓ 80.32%
Net Income	$-51.2M	↑ 110.04%
Net Profit Margin	-730.53%	↓ 662.08%

	Q3 FY23	Q/Q Change
Revenue	$16.5M	↑ 135.73%
Net Income	$-28.7M	↓ 43.92%
Net Profit Margin	-173.8%	↑ 556.73%

	Q4 FY23	Q/Q Change
Revenue	$16.9M	↑ 2.54%
Net Income	$-14.5M	↓ 49.52%
Net Profit Margin	-85.56%	↑ 88.24%

	Q1 FY24	Q/Q Change
Revenue	$10.0M	↓ 40.74%
Net Income	$-31.7M	↑ 118.57%
Net Profit Margin	-315.58%	↓ 230.02%

	Q2 FY24	Q/Q Change
Revenue	$19.2M	↑ 91.85%
Net Income	$-37.7M	↑ 19.06%
Net Profit Margin	-195.84%	↑ 119.74%

	Q3 FY24	Q/Q Change
Revenue	$16.0M	↓ 16.85%
Net Income	$-29.9M	↓ 20.79%
Net Profit Margin	-186.56%	↑ 9.28%

	FY18	Y/Y Change
Profit	$53.0M	↑ 399.33%

	FY19	Y/Y Change
Profit	$-87.6M	↓ 265.13%

	FY20	Y/Y Change
Profit	$39.0M	↓ 144.49%

	FY21	Y/Y Change
Profit	$26.7M	↓ 31.5%

	FY22	Y/Y Change
Profit	$412.5M	↑ 1446.03%

	FY23	Y/Y Change
Profit	$-67.0M	↓ 116.24%

	Q2 FY23	Q/Q Change
Profit	$-32.4M	↑ 229.5%

	Q3 FY23	Q/Q Change
Profit	$-16.4M	↓ 49.28%

	Q4 FY23	Q/Q Change
Profit	$-8.3M	↓ 49.51%

	Q1 FY24	Q/Q Change
Profit	$-22.7M	↑ 173.67%

	Q2 FY24	Q/Q Change
Profit	$16.7M	↓ 173.59%

	Q3 FY24	Q/Q Change
Profit	$13.3M	↓ 20.2%

	FY18	Y/Y Change
Operating Cash Flow	$24.2M	↑ 10939.73%
Investing Cash Flow	$-109.0M	↑ 253.04%
Financing Cash Flow	$91.4M	↑ 83.04%

	FY19	Y/Y Change
Operating Cash Flow	$-81.9M	↓ 438.56%
Investing Cash Flow	$-25.6M	↓ 76.53%
Financing Cash Flow	$193.7M	↑ 111.81%

	FY20	Y/Y Change
Operating Cash Flow	$-151.4M	↑ 84.97%
Investing Cash Flow	$-43.4M	↑ 69.74%
Financing Cash Flow	$309.0M	↑ 59.55%

	FY21	Y/Y Change
Operating Cash Flow	$-192.5M	↑ 27.11%
Investing Cash Flow	$144.6M	↓ 432.86%
Financing Cash Flow	$8.0M	↓ 97.41%

	FY22	Y/Y Change
Operating Cash Flow	$144.1M	↓ 174.88%
Investing Cash Flow	$-53.8M	↓ 137.24%
Financing Cash Flow	$108.6M	↑ 1255.41%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.4M	↓ 92.31%
Investing Cash Flow	$-60.7M	↓ 56.1%
Financing Cash Flow	$27.6M	↑ 1488.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-42.7M	↑ 566.78%
Investing Cash Flow	$-7.0M	↓ 88.43%
Financing Cash Flow	$1.9M	↓ 93.13%

Zymeworks Technicals Summary

Sell

Neutral

Buy

Zymeworks is currently in a neutral trading position according to technical analysis indicators.

Zymeworks (ZYME) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Zymeworks Inc	-13.27%	8.42%	4.25%	104.0%	-60.21%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Zymeworks Inc	3.56	NA	0.0	-1.44	-0.29	-0.15	NA	5.27
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Zymeworks Inc	Buy	$877.5M	-60.21%	3.56	-182.75%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Organization	Zymeworks
Employees	294
CEO	Mr. Kenneth H. Galbraith C.A.
Industry	Health Technology

Management People of Zymeworks

Name	Title
Mr. Kenneth H. Galbraith C.A.	Chairman of the Board, CEO & President
Dr. Paul A. Moore Ph.D.	Chief Scientific Officer
Mr. Mark Hollywood	Executive VP and Head of Technical & Manufacturing Operations
Ms. Shrinal Inamdar	Director of Investor Relations
Mr. Daniel Dex J.D., Ph.D.	Senior VP, Corporate Secretary & General Counsel
Diana Papove	Senior Manager of Corporate Communications
Dr. Lindsey Foulkes B.Sc., Ph.D.	Vice President of Corporate Development
Ms. Laura O'Connor	Vice President of Human Resources & DEI
Dr. Jeffrey Smith M.D.	Executive VP & Chief Medical Officer
Mr. John Fann Ph.D.	Senior Vice President of Process Sciences

Important FAQs about investing in ZYME Stock from India :

What is Zymeworks share price today?

Zymeworks share price today stands at $13.18, Open: $12.72 ; Previous Close: $12.75 ; High: $13.18 ; Low: $12.70 ; 52 Week High: $17.70 ; 52 Week Low: $7.97.

The stock opens at $12.72, after a previous close of $12.75. The stock reached a daily high of $13.18 and a low of $12.70, with a 52-week high of $17.70 and a 52-week low of $7.97.

Can Indians buy Zymeworks shares?

Yes, Indians can invest in the Zymeworks (ZYME) from India.

With INDmoney, you can buy Zymeworks at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Zymeworks at zero transaction cost.

How can I buy Zymeworks shares from India?

It is very easy to buy Zymeworks from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Zymeworks (ZYME) be purchased?

Yes, you can buy fractional shares of Zymeworks with INDmoney app.

What are the documents required to start investing in Zymeworks stocks?

To start investing in Zymeworks, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.